Session Title: Vitreoretinal Surgery IV
Session Date/Time: Friday 27/09/2013 | 16:30-18:00
Paper Time: 16:54
Venue: Hall 3 (Level 0)
First Author: P.Saikia INDIA
To compare the outcomes of topical nepafenac 0.1% ophthalmic suspension and prednisolone acetate 1% ophthalmic suspension in controlling inflammation and pain following 23-gauge vitreoretinal surgery.
Chandraprabha Eye Hospital, Jorhat, India
One hundred and nineteen subjects (123eyes) with vitreous hemorrhage and uncomplicated pseudophakic rhegmatogenous retinal detachment were enrolled for study after receiving informed consent. Subjects were randomized to receive topical nepafenac 0.1% (nepafenac group) and prednisolone acetate 1% (steroid group) post operatively. Data were collected on post operative day1, 7, 14 and 30. On day4 information was collected about pain over telephone. Success was defined as pain score 0 on day4 and cell score 0.5 or less on day30. Analysis included post operative pain, inflammation and complication.
The nepafenac group consisted of 56 subjects (59 eyes), and steroid group 63 subjects (64 eyes). Between group difference in pain was not statistically significant on post operative day1 (p=0.122) and day4 (p=0.086). Inflammation was statistically significantly higher in nepafenac group on day7 (p=0.001) and day14 (p=0.002), but not statistically significant on day1 (p=0.951) and day30 (p=0.174). There was no serious complication noted in both the groups.
Nepafenac 0.1% ophthalmic suspension is as effective as prednisolone acetate 1% ophthalmic suspension in controlling pain and inflammation following 23-gauge vitreoretinal surgery without serious complication.